Genome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy

Cell Mol Life Sci. 2023 Jul 21;80(8):220. doi: 10.1007/s00018-023-04852-2.

Abstract

The precise characterization of oxygen-sensing pathways and the identification of pO2-regulated gene expression are both issues of critical importance. The O2-sensing system plays crucial roles in almost all the pivotal human processes, including the stem cell specification, the growth and development of tissues (such as embryogenesis), the modulation of intermediate metabolism (including the shift of the glucose metabolism from oxidative to anaerobic ATP production and vice versa), and the control of blood pressure. The solid cancer microenvironment is characterized by low oxygen levels and by the consequent activation of the hypoxia response that, in turn, allows a complex adaptive response characterized mainly by neoangiogenesis and metabolic reprogramming. Recently, incredible advances in molecular genetic methodologies allowed the genome editing with high efficiency and, above all, the precise identification of target cells/tissues. These new possibilities and the knowledge of the mechanisms of adaptation to hypoxia suggest the effective development of new therapeutic approaches based on the manipulation, targeting, and exploitation of the oxygen-sensor system molecular mechanisms.

Keywords: CRISPR/Cas9; Genome editing; Hypoxia sensitive-CAR T; Hypoxia-inducible factor; PHD; Von Hippel-Lindau.

Publication types

  • Review

MeSH terms

  • Cell Hypoxia / genetics
  • Gene Editing*
  • Humans
  • Hypoxia / genetics
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • Oxygen / metabolism
  • Tumor Microenvironment / genetics
  • Von Hippel-Lindau Tumor Suppressor Protein / genetics

Substances

  • Oxygen
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Von Hippel-Lindau Tumor Suppressor Protein